Conjugate vaccines have played a key role in preventing life-threatening diseases worldwide. However, many people remain unaware of what exactly conjugate vaccines are and how they work.
What are conjugate vaccines?
Conjugate vaccines link bacterial polysaccharides, also known as capsular polysaccharides, to protein carriers like tetanus toxoid. Polysaccharides can effectively induce immunity against bacterial infections, but on their own elicit a poor immune response in infants and young children whose immune systems have not fully developed. By chemically attaching polysaccharides to protein carriers, conjugate vaccines actively engage the immune system's T-cell dependent pathway to generate a stronger, longer-lasting immune response even in young children.
Mechanism of action
When a Conjugate Vaccine is administered, both the polysaccharide and carrier protein stimulate the immune system. The protein element activates T-helper cells which then help B-cells proliferate and differentiate into memory B-cells and plasma cells. The plasma cells produced secrete antibodies specifically targeted against the polysaccharide capsule of the bacterium. The generation of memory B-cells ensures long-term protection through quicker recollection of antibody production if re-exposed to infection. In comparison, plain polysaccharide vaccines only activate the T-cell independent response, producing short-lived antibodies of limited protection, especially in infants.
Diseases targeted and effectiveness
Some major bacterial diseases now successfully prevented through Conjugate Vaccines include:
Pneumococcal disease - Caused by Streptococcus pneumoniae, it was a leading cause of pneumonia, meningitis and death in children prior to vaccination. Pneumococcal conjugate vaccines have reduced invasive pneumococcal disease by over 95% in vaccinated children.
Meningococcal disease - Neisseria meningitidis can cause life-threatening meningitis and sepsis. Conjugate meningococcal vaccines have controlled serogroups A, C, Y and W-135 disease worldwide.
Haemophilus influenzae type b (Hib) - This bacterium was a primary cause of invasive diseases like meningitis, pneumonia and epiglottitis before Hib conjugate vaccination. It has virtually eliminated Hib disease in highly vaccinated countries.
Salmonella Typhi - The typhoid conjugate vaccine offers longer and broader protection against typhoid fever compared to the older polysaccharide vaccine.
Development and regulatory approvals
Pioneering conjugate vaccine development began in the 1970s and 80s. It involved identifying the safest and most immunogenic capsular polysaccharides, developing conjugation chemistries and evaluating candidate vaccines in rigorous clinical trials. The first licensed conjugate vaccines targeted Hib and meningococcal group C. They obtained regulatory approvals in the 1990s and were gradually introduced worldwide through national immunization programs. Currently several countries have conjugate vaccines against pneumococcus, meningococcus and Salmonella Typhi included in their routine pediatric immunization schedules.
Importance of conjugate vaccines
By conferring robust, long-lasting protection even in young children, conjugate vaccines have significantly reduced severe bacterial infections and related mortality globally. This is especially critical in developing nations where such diseases once heavily burdened vulnerable populations like infants and toddlers. Conjugate vaccines have also helped eliminate antibiotic-resistant superbugs by controlling infections that previously drove antibiotic overuse. Their widespread use exemplifies the potential of modern vaccine technology to conquer deadly pathogens through pediatric immunization. Ongoing research aims to develop new conjugate vaccines against tuberculosis, Group B streptococcus and other harmful bacteria. If successfully developed and deployed, they could further minimize the impact of infectious diseases worldwide.
Explore Our More Blogs on Conjugate Vaccine
Also Read Related Article on Smartwatches and Fitness Trackers
Global Vaccine Market by Type, Application, Regions and by Key Players, Forecast to 2026 documents an overview of the market trends, competitive structure, market shares of the competitors, market demands, market drivers, market restraints, and product analysis, and.
The report presents a detailed analysis of global Vaccine market size on regional and country-level, recent developments, segmentation market growth, strategic market growth analysis, opportunities analysis, and product launches.
Competitive landscape provides details by vendors, including company overview, global presence, company financials, market share, market potential, sales and revenue generated, price, consumption and production sales, SWOT analysis.DOWNLOAD SAMPLE REPORT: https://www.reportcrux.com/request-sample-report/Top-20-Vaccine-Companies-In-depth-Analysis-2020-Sanofi-Pfizer-GlaxoSmithKline-GSK-Merck--Co-AstraZeneca-Emergent-BioSolutions-Mitsubishi-Tanabe-Pharma-Seqirus-CSL-Limited-Other-CompaniesMarketThe report highlights in-depth quantitative as well as qualitative insights, historical data, and market size projections till 2026.
Value chain analysis of the industry is explained in detail this providing a clear view of key mediators involved.
The report studies the global Vaccine market size from the company, major regions and countries, products type, end users and applications, background information, and also predictions to 2026.In depth competitive landscaping, recent developments by competitors and product pipelines are covered in the report.
Key market players in the global Vaccine market, consist of Sanofi Pasteur • GlaxoSmithKline (GSK) • Merck & Co., Inc. • Pfizer • AstraZeneca • Mitsubishi Tanabe Pharma • Emergent BioSolutions • Astellas Pharma Inc. • Valneva • Seqirus(CSL Limited) • Bavarian Nordic • Sinovac • Panacea Biotec • Dynavax Technologies Corporation • Bharat Biotech • Serum Institute of India • Biological E. Limited • Grifols • Hualan Biological Engineering Inc • Gamma Vaccines Pty LtdRequest for Research Methodology: https://www.reportcrux.com/research-methodology/Top-20-Vaccine-Companies-In-depth-Analysis-2020-Sanofi-Pfizer-GlaxoSmithKline-GSK-Merck--Co-AstraZeneca-Emergent-BioSolutions-Mitsubishi-Tanabe-Pharma-Seqirus-CSL-Limited-Other-CompaniesMarketRegional Analysis:Based on region, the market report is segmented into five main regions i.e.
Meningococcal Vaccines Market Attractiveness Analysis, Forecast Period 2019 – 2025.
The Global Market is based on Industry Size, Share, Trend and Growth.
Meningococcal vaccines are vaccines used for preventing infection caused by Neisseria meningitidis.
Subcapsular vaccine, polysaccharide, and meningococcal conjugate vaccine are the different types of vaccines effective against all or some of these meningococcus types- A, B, C, Y, and W-135.
Meningococcal Vaccines Market Regional Analysis Based on the region, the global meningococcal vaccines market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA).
Factors propelling the market growth include an increase in disease outbreaks, easy availability of products, increasing awareness about the disease, rapid adoption of advanced products, and increasing penetration of new entrants with new technology.
The Pneumococcal Conjugate Vaccine Market 2021 research report gives emerging industry data, global segments and regional outlook.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the pneumococcal conjugate vaccine market include Glaxosmithkline plc, LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Pneumococcal Conjugate Vaccine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/pneumococcal-conjugate-vaccine-market/download-sampleMarket DynamicsPneumococcal disease, one of the leading vaccine-preventable disorders, and one of the major causes of young children’s mortality rate worldwide is the key trend driving this market’s growth.
The demand for this vaccine is on the rise since it effectively prevents antibiotic-resistant pneumococcal infections caused by vaccine serotypes and the spread of the bacteria in the community.
